JSPR Jasper Therapeutics
- 23.820
- -0.350-1.45%
- 24.360
- +0.540+2.27%
Jasper Therapeutics News
Jasper Therapeutics Analyst Ratings
Jasper Therapeutics Analyst Ratings
Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment
Analysts' Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)
Jasper Therapeutics Analyst Ratings
Buy Rating for Jasper Therapeutics: Promising Prospects for Briquilimab in Treating Chronic Urticaria
Jasper Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)
Buy Rating Affirmed: Jasper Therapeutics' Progress and Potential in Addressing Unmet Needs in Chronic Urticaria Treatment
Oppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)
Buy Rating on Jasper Therapeutics Highlighting Briquilimab's Potential in Chronic Urticaria Treatment
Buy Rating for Jasper Therapeutics: Promising Developments in CSU Treatment Pipeline and Anticipated Clinical Milestones
Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target
Jasper Therapeutics Analyst Ratings
Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target
Jasper Therapeutics Analyst Ratings
Jasper Therapeutics Analyst Ratings
EF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)
EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target
EF Hutton Assumes Jasper Therapeutics at Buy, Announces Price Target of $6.85
Analysis
Price Target
No Data
